Member Info for Parpaing

Xenetic Biosciences, Inc. Enters Into Asset Purchase Agreement With Financing Component for the Rights to Develop, Market and License Oncologic Drug Candidate Virexxa™ The APA also contains a financing component wherein the Company will receive from Pharmsynthez up to $3.5 million in bridge financing and a commitment of an additional $6.5 million in financing as part of a planned capital raise of at least $15 million and up-list to a national securities exchange. "This transaction provides us with our first U.S. FDA IND-enabled clinical candidate for an orphan cancer indication," said M. Scott Maguire, Chief Executive Officer of Xenetic Biosciences. "Virexxa with orphan designation in the U.S. adds to our Phase II portfolio which also includes ErepoXen, our long-acting anemia drug candidate. As well as expanding our pipeline, the Company is pleased to receive financial commitments of up to $10M to fund our further development, as well as financial commitments to back our planned uplisting to a national securities exchange, an objective that remains a priority for the Company's board."

Well that good news RNS went down like a cup of cold vomit. Why hasn't this share soared on the good news?

The SP passed the usd mark at 1.07 yesterday. High fives all round.

Nearly 60 cents. Won't be long before its a dollar. I assume that with the locked -in agreement we may see an upgrade to the main market in the not too distant future. Then what? 5-10 dollars? That would make a great crimbo prezzy.

Looking good !

See the video at; http://biomebioplastics.com/video-investigating-lignin-with-warwick-university/

Warwick university has discovered three of the four target compounds from lignin. Very exciting. See: http://biomebioplastics.com/video-investigating-lignin-with-warwick-university/

Underwriters in IPOs and insiders of the issuing company agree on lock-ups to prevent the insiders from selling their stock within a given time window after the IPO. This time window normally amounts to 180 days. The lock-up agreement attempts to ensure the stability of the issuing company and to align insiders' incentives with the goals of the company. After the expiration of the lock-up period, insiders are free to sell, but potentially have to take into account insider regulation prevalent in many countries. Empirical evidence shows that the expiration of the lock-up agreements is often associated with negative stock returns for the company's stock. Example An underwriter might, for example, be concerned that the pre-IPO owners of a firm may know that their firm is overvalued or even engaged in window dressing to let the firm appear as profitable as possible. By restricting their stock sales for a certain period of time, the underwriter hopes that markets use this time before the lock-up expiration to figure out the true value of a company. Insiders could thus be deterred from engaging in opportunistic behaviour before or at the IPO.

£8000 into £400. "Invest" in TRP.

Scott is an accountant? For Mr.Leeson to add to his repertoire: C'est quoi un comptable, c'est un con avec une table !

Good news for BIOM. France is banning single-use plastic bags from January 2016 unless they are biodegradable and from a vegetable source.

Xenetic Biosciences Commences Third Cohort of Phase 2 Trials on Drug Candidate ErepoXen(R) for Anemia Trial expands into South Africa Compound uses Patented PolyXen® Technology for Recombinant Erythropoietin LEXINGTON, Mass., Sept. 16, 2015 (GLOBE NEWSWIRE) -- Xenetic Biosciences, Inc. (OTCQB:XBIO), a biopharmaceutical company focused on developing next-generation biologic drugs and novel oncology therapeutics, announced today that it has commenced the third cohort of its Phase 2 dose-escalation study with its lead drug candidate ErepoXen® for the treatment of anemia in pre-dialysis chronic kidney disease patients. In an effort to accelerate the recruitment rate, Xenetic has expanded the clinical research sites beyond Australia to now include locations in South Africa. Subjects from this third cohort study will receive injections of ErepoXen® every two weeks until hemoglobin levels reach therapeutic levels. The patients will then receive injections of ErepoXen® every 4 weeks (extended dosing interval) during maintenance for a total trial time of 17 weeks. The data from the second cohort showed that 91% of the enrolled patients had an increase in hemoglobin levels over time, and that in 75% of the enrolled patients, hemoglobin levels rose into the therapeutic range. The third cohort is designed to further increase the patient's hemoglobin levels into mid-therapeutic range. The study is being performed at nine clinical sites in Australia and six new clinical sites in South Africa. Patient treatment has commenced in Australia. National and local regulatory approvals have been granted in South Africa and patient treatment is expected to start in September. This cohort is expected to be completed in Q2, 2016. "We expect Cohort three to be the final leg of this phase II trial," said M. Scott Maguire, Chief Executive Officer of Xenetic. "We are excited to share this update with shareholders as the Company progresses along the developmental pathway of our ErepoXen® drug candidate.

http://money.cnn.com/news/newsfeeds/articles/globenewswire/5924051.htm

Xenetic Biosciences (XBIO) Contracts With Baxter International Inc Have Been Assigned to Baxalta Incorporated Following the Company Spin Out. As a result of a revised license deal in January 2014, the Company is entitled to up to $100 million in potential development, regulatory, sales and deadline extension receipts, which are contingent on the performance of Baxalta achieving certain milestones. The Company is also entitled to royalties on potential net sales. In connection with this deal, Baxalta also made a $10 million equity investment at a price of $0.935 per share, which is a post money market cap of approximately $140 million.

"Xenetic is planning to launch an initial public offering on the Nasdaq stock exchange by the end of June", according to the article. I am assuming June 2016 as June 2015 has passed and the article was posted on September 5th 2015. If it would be June 2017, then I don't think Scott Maguire can wait that long.

Many thanks for the post - IPO planned in June next year then. Excellent news.

our xbio shares change from red to green!

Another rise today and a lack of jesting by Mr. Lesson. More japes please.

Bonjovi Everyone, Just back from three weeks at El Cheapo on the Costa Lotta. Still rooting for XBIO and looking forward to the impending IPO.

Biome is pleased to announce that its Stanelco RF Technologies division has signed a £1.1m contract with a customer in Asia for the manufacture of a set of fibre optic furnaces for supply during 2015. It was noted in the Group’s trading update on 27 April 2015 that there were encouraging signs that the supply demand balance in the Asian fibre optic market was changing and that the division was quoting on a number of systems with potential customers who were considering new capacity. This order is indicative of the improvement in market conditions and gives significant underpinning to the Board’s expected outcome for this division in 2015